AIDS Therapies (Clinical Trials)

HIV Patients Initiated in Low Dose Oral Alpha Interferon Study

Published in AIDS Weekly, June 17th, 1996

Interferon Sciences, Inc., New Brunswick, New Jersey, announced the participation in a randomized, placebo-controlled, multicenter study examining the effectiveness of low dose oral alpha interferon (LDOAI) therapy in reducing the symptoms of AIDS.

Patient enrollment in this study, which is sponsored by the U.S. National Institute of Allergy and Infectious Diseases (NIAID), has commenced and will include 560 people infected with HIV once enrollment is completed. In this study, three preparations of LDOAI, including Alferon LDO and two other brands of LDOAI from foreign sources are compared to a placebo.

The trial design was the result of joint...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (1996-06-17)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry